RU2020119065A - Маркеры болезни фарбера и их применения - Google Patents

Маркеры болезни фарбера и их применения Download PDF

Info

Publication number
RU2020119065A
RU2020119065A RU2020119065A RU2020119065A RU2020119065A RU 2020119065 A RU2020119065 A RU 2020119065A RU 2020119065 A RU2020119065 A RU 2020119065A RU 2020119065 A RU2020119065 A RU 2020119065A RU 2020119065 A RU2020119065 A RU 2020119065A
Authority
RU
Russia
Prior art keywords
cd11b
mhcii
level
subject
determining
Prior art date
Application number
RU2020119065A
Other languages
English (en)
Russian (ru)
Other versions
RU2020119065A3 (enExample
Inventor
Кристина КОКЕРИ
Брант СЭМПИ
Original Assignee
Асераген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Асераген Инк. filed Critical Асераген Инк.
Publication of RU2020119065A publication Critical patent/RU2020119065A/ru
Publication of RU2020119065A3 publication Critical patent/RU2020119065A3/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2020119065A 2018-03-27 2019-03-22 Маркеры болезни фарбера и их применения RU2020119065A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648775P 2018-03-27 2018-03-27
US62/648,775 2018-03-27
PCT/IB2019/000290 WO2019186272A1 (en) 2018-03-27 2019-03-22 Farber disease markers and uses thereof

Publications (2)

Publication Number Publication Date
RU2020119065A true RU2020119065A (ru) 2022-04-27
RU2020119065A3 RU2020119065A3 (enExample) 2022-07-14

Family

ID=66530353

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020119065A RU2020119065A (ru) 2018-03-27 2019-03-22 Маркеры болезни фарбера и их применения

Country Status (16)

Country Link
US (2) US20190302126A1 (enExample)
EP (1) EP3775924A1 (enExample)
JP (2) JP2021516757A (enExample)
KR (2) KR20240111011A (enExample)
CN (2) CN111971562A (enExample)
AU (1) AU2019244477A1 (enExample)
BR (1) BR112020016435A2 (enExample)
CA (1) CA3090354A1 (enExample)
CL (1) CL2020002105A1 (enExample)
CO (1) CO2020010043A2 (enExample)
IL (2) IL311212A (enExample)
MX (1) MX2020008377A (enExample)
PH (1) PH12020551206A1 (enExample)
RU (1) RU2020119065A (enExample)
SG (1) SG11202007508TA (enExample)
WO (1) WO2019186272A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220088158A1 (en) * 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
CA3209730A1 (en) * 2021-03-29 2022-10-06 Alan Parker Modified adenovirus
CN117647649A (zh) * 2023-08-15 2024-03-05 迈健医药科技无锡有限公司 一种免疫细胞全维分析的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
CA2163860A1 (en) 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
JP6832158B2 (ja) 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
EP3115786A1 (en) * 2015-07-08 2017-01-11 Centogene AG Method for the diagnosis of farber's disease

Also Published As

Publication number Publication date
BR112020016435A2 (pt) 2020-12-15
KR20200136367A (ko) 2020-12-07
MX2020008377A (es) 2020-09-25
CO2020010043A2 (es) 2020-11-10
PH12020551206A1 (en) 2021-04-19
EP3775924A1 (en) 2021-02-17
CN111971562A (zh) 2020-11-20
SG11202007508TA (en) 2020-09-29
CL2020002105A1 (es) 2020-12-04
CN118112249A (zh) 2024-05-31
JP2021516757A (ja) 2021-07-08
US20190302126A1 (en) 2019-10-03
IL311212A (en) 2024-05-01
WO2019186272A1 (en) 2019-10-03
US20210199670A1 (en) 2021-07-01
AU2019244477A1 (en) 2020-06-25
CA3090354A1 (en) 2019-10-03
JP2023159164A (ja) 2023-10-31
KR20240111011A (ko) 2024-07-16
IL276420A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
Murakami et al. Chemokine receptors and melanoma metastasis
Lotz et al. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis
ES2310931T3 (es) Analogos de interferon alfa humano de baja toxicidad.
ES2279575T3 (es) Analogos de peptidos derivados de receptores del factor de necrosis tumoral.
Mellstedt et al. Interferon therapy in myelomatosis
US20200188471A1 (en) Application of selective tnfr1 antagonist peptide sn10 in preparation of drugs for preventing and treating rheumatoid arthritis
US20220073530A1 (en) PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
MX2007009235A (es) Composiciones y metodos para tratar desordenes fibroticos.
JPH05170661A (ja) 薬剤組成物
JPH0840933A (ja) Ｌｅｕ３表現型Ｔ細胞媒介性自己免疫病の治療用組成物
Liss et al. Correlation of 5-Fluorouracil (NSC-19893) Distribution in Rodents With Toxicity and Chemotherapy in Man 1, 2, 3
JP2021516757A5 (enExample)
JPH11506737A (ja) 小細胞肺ガンを治療または検出するためのコノトキシンペプチドｕ００２およびｍｉｉの使用
HRP20030215A2 (en) Chemokine mutants in the tratment of multiple sclerosis
KR101736280B1 (ko) 관절염 예방 또는 치료용 약학적 조성물
JPH07563B2 (ja) 好酸球増加症の予防または鎮静用薬剤
ATE191502T1 (de) Corticotropinauslösefaktor-bindendes protein
Labuda et al. Tick-borne encephalitis virus activity in Styria, Austria
CN1421459A (zh) 人源化抗cd3单克隆抗体
JPH0544930B2 (enExample)
CN103333236B (zh) 一种优秀冰雪运动员血管紧张素转化酶部分多肽多克隆抗体制备方法
Yang et al. Identification of the mouse calcium‐binding proteins, MRP 8 and MRP 14, in Schistosoma mansoni‐induced granulomas: biochemical and functional characterization
RU2013157328A (ru) Пептидные и непептидные лиганды для иммунодетекции рецептора уротензина ii
CN102250239B (zh) 一种与兔出血症病毒vp60蛋白相结合的蛋白及其应用
van Mook et al. A rare case of disseminated actinomycosis caused by Actinomyces meyeri